Oncolytics (ONCY) Biotech announced the appointment of Jared Kelly as CEO and a member of its Board of Directors. Kelly is a successful biotech executive who has proven expertise in transformative deals and corporate strategy. Most recently, he played a central role in orchestrating the sale of Ambrx Biopharma to Johnson & Johnson for $2B. Prior to Ambrx, he advised multiple leading-edge biotech companies on M&A and licensing transactions at highly respected law firms, including Lowenstein Sandler LLP and Kirkland & Ellis LLP. He is a JD and LLM graduate of Georgetown Law.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONCY:
- Oncolytics Biotech Unveils Promising Pelareorep Data at ASCO 2025
- Oncolytics presents new data from Phase I/II GOBLET clinical trial
- Promising Clinical Developments and Strategic Advancements Justify Buy Rating for Oncolytics Biotech
- Oncolytics downgraded to Hold from Buy at JonesResearch
- Oncolytics Biotech’s Strategic Advances in Oncology: Promising Developments in Breast and Pancreatic Cancer Research